The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective

被引：0
|
作者：
F. Borgström
Å. Carlsson
H. Sintonen
S. Boonen
P. Haentjens
R. Burge
O. Johnell
B. Jönsson
J. A. Kanis
机构：
[1] Stockholm Health Economics,Medical Management Centre
[2] Karolinska Institutet,Department of Public Health
[3] University of Helsinki,Leuven University Center for Metabolic Bone Diseases and Division of Geriatric Medicine
[4] Katholieke Universiteit Leuven,Department of Orthopaedics and Traumatology
[5] Academisch Ziekenhuis van de Vrije Universiteit Brussel,Division of Pharmaceutical Sciences, College of Pharmacy
[6] Procter & Gamble Pharmaceuticals,Department of Orthopaedics
[7] University of Cincinnati,Department of Economics
[8] Malmö General Hospital,Centre for Metabolic Bone Diseases (WHO Collaborating Centre)
[9] Stockholm School of Economics,undefined
[10] University of Sheffield Medical School,undefined
来源：
Osteoporosis International | 2006年 / 17卷
关键词：
Belgium; Cost-effectiveness; Finland; Fracture; Osteoporosis; Postmenopausal women; Risedronate; Spain; Sweden;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：996 / 1007
页数：11
相关论文
共 50 条
  • [31] Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis
    Zethraeus, N
    Ben Sedrine, W
    Caulin, F
    Corcaud, S
    Gathon, HJ
    Haim, M
    Johnell, O
    Jönsson, B
    Kanis, JA
    Tsouderos, Y
    Reginster, JY
    [J]. OSTEOPOROSIS INTERNATIONAL, 2002, 13 (11) : 841 - 857
  • [32] Cost-effectiveness of Denosumab for the Treatment of Postmenopausal Osteoporosis in Malaysia
    Y. W. Choo
    N. A. Mohd Tahir
    M. S. Mohamed Said
    S. C. Li
    M. Makmor Bakry
    [J]. Osteoporosis International, 2022, 33 : 1909 - 1923
  • [33] Modelling cost-effectiveness in osteoporosis
    Kanis, John A.
    Adams, Judith
    Borgstrom, Fred
    Cooper, Cyrus
    Jonsson, Bengt
    Preedy, Danielle
    Selby, Peter
    Compston, Juliet
    [J]. BONE, 2008, 43 (01) : 215 - 216
  • [34] Cost-effectiveness research in osteoporosis
    Coyle, D
    Cranney, A
    Lee, KM
    Welch, V
    Tugwell, P
    [J]. DRUG DEVELOPMENT RESEARCH, 2000, 49 (03) : 135 - 140
  • [35] Impact of Generic Alendronate Cost on the Cost-Effectiveness of Osteoporosis Screening and Treatment
    Nayak, Smita
    Roberts, Mark S.
    Greenspan, Susan L.
    [J]. PLOS ONE, 2012, 7 (03):
  • [36] Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis
    Berto, Patrizia
    Maggi, Stefania
    Noale, Marianna
    Lopatriello, Stefania
    [J]. AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2010, 22 (02) : 179 - 188
  • [37] Cost-effectiveness of Fosamax® (alendronate) for the treatment of osteoporosis and prevention of fractures
    Johnell, O
    Jönsson, B
    Jönsson, L
    Black, D
    [J]. OSTEOPOROSIS INTERNATIONAL, 2000, 11 : S9 - S9
  • [38] COST-EFFECTIVENESS OF TREATMENT FOR POST-MENOPAUSAL OSTEOPOROSIS IN BRAZIL
    Brandao, C. M. R.
    Machado, G. P. D. M.
    Saturnino, L. T. M.
    Oliveira, G. L. A. D.
    Acurcio, F. D. A.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A717 - A717
  • [39] Ibandronate in the treatment of postmenopausal osteoporosis: A cost-effectiveness analysis in the UK
    Earnshaw, S.
    Lynch, N. O.
    Cowell, W.
    Beard, S.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 416 - 416
  • [40] A systematic review of cost-effectiveness analyses of sequential treatment for osteoporosis
    Yu, Guangyi
    Tong, Suiju
    Liu, Jinyu
    Wan, Yuansheng
    Wan, Min
    Li, Sujuan
    You, Ruxu
    [J]. OSTEOPOROSIS INTERNATIONAL, 2023, 34 (04) : 641 - 658
12345